What IGF-LR3 / MOTS-c Blend actually is

This pair combines IGF-1 LR3 (the long-acting IGF-1 analogue with reduced IGFBP binding) with MOTS-c, the 16-amino-acid mitochondrial-encoded peptide.¹ IGF-1 LR3 drives anabolic and tissue-repair signaling; MOTS-c overlays AMPK activation and exercise-mimetic gene programs.²

The pairing fits patients prioritizing recovery and performance without engaging the pituitary directly — useful when GH/IGF axis is intact but specific tissue effects (muscle, tendon, mitochondrial fitness) are the goal.

At Luxbae, IGF-LR3 / MOTS-c Blend is prescribed and supervised by Dr. Ernst von Schwarz, MD, PhD after a complimentary medical consultation.

Mechanism — Anabolic plus mitochondrial

IGF-1 LR3 drives PI3K/Akt/mTOR anabolism in muscle and connective tissue; MOTS-c engages AMPK for mitochondrial efficiency.¹

What the research shows

Muscle protein synthesis. Direct IGF-1 drives anabolic signaling at receptor.

Mitochondrial fitness. MOTS-c improves mitochondrial efficiency and exercise tolerance in animal data.²

Connective tissue. IGF-1 supports tendon and ligament matrix biology.³

Side effects: Hypoglycemia risk from IGF-1 LR3, injection-site reactions, transient warmth from MOTS-c.

FDA note: Neither component is FDA-approved as a compounded blend.

IGF-LR3 / MOTS-c Blend FAQ

Why pair these two?
Anabolic (IGF) plus mitochondrial (MOTS-c) — complementary axes.

Hypoglycemia risk?
From the IGF component — monitored carefully.

References

1. Tomas FM, et al. IGF-I and more potent variants. Biochem J. 1991;276(Pt 2):547-554.
2. Lee C, Zeng J, Drew BG, et al. MOTS-c. Cell Metab. 2015;21(3):443-454.
3. Velloso CP. Regulation of muscle mass by GH and IGF-I. Br J Pharmacol. 2008;154(3):557-568.